Silverback Therapeutics is a private biopharmaceutical company pioneering a new class of immune-modulating ImmunoTAC™ drug conjugates targeting previously inaccessible disease pathways.
Silverback Therapeutics is charting a new path for treating a range of severe diseases.
Silverback Therapeutics was founded in 2016 by Peter Thompson. The company is headquartered in Seattle, Washington.
Silverback Therapeutics is developing therapies that act on fundamental biological pathways that underlie disease, but that modern medicine has not been able to fully harness — until now.
Silverback’s ImmunoTAC™ platform enables local modulation of powerful biologic pathways enabling innovative therapeutic approaches to oncology, virology and fibrotic diseases.
Silverback’s lead candidate, SBT6050, directly and potently activates myeloid cells in HER2-containing tumors leading to eradication of the cancer cells and reprogramming of the tumor microenvironment in preclinical models.
Silverback Therapeutics is backed by U.S. Venture Partners (“USVP”), OrbiMed Advisors LLC, Bristol-Meyers Squibb, Nextech Invest Ltd., Hunt Investment Group and others. The company raised $78.5M in a Series B round on Mar 11, 2020. This brings Silverback's total funding to $126M to date.